Together, these findings delineate a cross-scale pathogenic axis in which PPAR-γ–mediated regulation of both adaptive and innate IL-17 production links genetic susceptibility, cellular dysregulation, and clinical phenotypes in SSc and PsO. This evidence concerns the gene PPARG and systemic sclerosis.